Search Results
Mar 03, 2026, 09:48 ET New Research Finds Peanut Butter Consumption Builds Muscle Power in Older Adults
Reynolds JC, Marinik EL, Kolb RD, Lozano AJ, Davy BM, Hunter GR, Larson-Meyer DE. A Randomized Trial of Healthy Weight Gain in Athletic Individuals. Med Sci Sports Exerc. 2024 Mar 25. doi: 10.1249/MSS.0000000000003427. Epub ahead of print. PMID: 38537251.Baer DJ, Dalton M, Blundell J, Finlayson G,
More news about: The Peanut Institute
Mar 02, 2026, 09:10 ET XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
three consecutive FDA-NMPA registrational trial clearances for its universal iPSC-derived cell therapies targeting Parkinson's Disease (PD), Spinal Cord Injury (SCI), and Amyotrophic Lateral Sclerosis (ALS), respectively. Building on its promising clinical data, the rapid pipeline progress fully attests to XellSmart's
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Mar 02, 2026, 06:00 ET Paralyzed Veterans of America Celebrates 80 Years of Impact and Influence, Invites Public At Large to Help Fuel the Power of PVA
You Can! is one of the most requested and downloaded PVA publications of all time. Written by VA SCI/D clinicians across the country, the manual is designed for newly injured patients living with SCI, their families, and caregivers. The latest edition, which is being soft launched exclusively to VA
More news about: Paralyzed Veterans of America
Feb 27, 2026, 16:30 ET FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial, Front. Vet. Sci., 19 January 2026(2)
More news about: Innocan Pharma Corporation
Feb 27, 2026, 16:30 ET FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial, Front. Vet. Sci., 19 January 2026(2)
More news about: Innocan Pharma Corporation
Feb 27, 2026, 12:36 ET BestQool's BQ60Pro: Next-Generation 6-Wavelength Home Red Light Therapy Device with Enhanced Output and Smarter Flexibility
Serafim KG, Ramos Sde P, de Lima FM, et al. Effects of 940 nm LED on sciatic nerve regeneration in rats. Lasers Med Sci. 2012;27(1):113-9
More news about: Bestqool
Feb 26, 2026, 06:30 ET Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
BK, & Sloop KW, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company
Feb 25, 2026, 08:30 ET Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
Randlov, J, Poulsen, JU. How Much Do Forgotten Insulin Injections Matter to Hemoglobin A1c in People with Diabetes, J Diabetes Sci Technol. 2008; 2(2):229-235.2
More news about: Medtronic plc
Feb 24, 2026, 10:00 ET Kevin Schewe's "Bad Love Strikes" Wins HASTFW Screenplay Category at London Director Awards
Kevin Schewe and the Bad Love Gang are thrilled to announce that Bad Love Strikes has been awarded the Winner of the HASTFW (Horror, Action, Sci-Fi, Thriller, Fantasy, Western) Screenplay Category at the internationally acclaimed London Director Awards, one of the TOP 100 Best Reviewed
More news about: Dr. Kevin Schewe
Feb 24, 2026, 09:00 ET Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market
In Vivo Analysis of the Biocompatibility and Immune Response of Jellyfish Collagen Scaffolds and its Suitability for Bone Regeneration. Int J Mol Sci. 2020 Jun 25;21(12):4518.Bowen A.J, et al. Larynx proteomics after jellyfish collagen IL: Increased ECM/collagen and suppressed inflammation.
More news about: Royal Biologics
Feb 24, 2026, 08:00 ET William Shatner's "World's Oldest Intern" Surpasses 2 Million Views as LifeWave Expands Series
playing an unlikely intern in his nineties as he explores LifeWave's futuristic Welcome Center with characteristic dry wit. The sketch‑style format and sci‑fi‑inspired humor have contributed to unusually high share‑through rates for a branded entertainment piece."They gave me a badge, called me an
More news about: LifeWave, Inc.
Feb 22, 2026, 04:51 ET Lenire muestra resultados positivos consistentes para pacientes con tinnitus en Estados Unidos
múltiples centros. Nature communications (2024)7. Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)8. Conlon et al., Diferentes ajustes de neuromodulación bimodal reducen los síntomas del tinnitus en un gran ensayo aleatorio, Sci Rep.9. Informe sobre las prestaciones del Departamento de
More news about: Neuromod Devices
Feb 19, 2026, 13:25 ET Une première mondiale en soins néonatals : le Japon approuve les fortifiants 100 % à base de lait humain de Prolacta Bioscience en tant que médicament sur ordonnance pour les nourissons vulnérables
JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely pretermants infants in Japan :
More news about: Prolacta Bioscience
Feb 19, 2026, 13:23 ET Eine Weltneuheit in der Neugeborenenpflege: Japan genehmigt die zu 100 % aus Muttermilch hergestellten Nahrungsergänzungsmittel von Prolacta Bioscience als verschreibungspflichtiges Medikament für gefährdete Säuglinge.
JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely preterm infants in Japan: past,
More news about: Prolacta Bioscience
Feb 19, 2026, 11:53 ET SERVICE CORPORATION INTERNATIONAL DECLARES QUARTERLY CASH DIVIDEND
HOUSTON, Texas, Feb. 19, 2026 /PRNewswire/ -- Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today announced that its Board of Directors has approved a quarterly cash
More news about: Service Corporation International
Feb 19, 2026, 03:26 ET Japón aprueba los fortificantes de Prolacta Bioscience, elaborados 100% con leche materna
JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely preterm infants in Japan: past,
More news about: Prolacta Bioscience
Feb 19, 2026, 02:00 ET A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely preterm infants in Japan: past,
More news about: Prolacta Bioscience
Feb 19, 2026, 02:00 ET A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely preterm infants in Japan: past,
More news about: Prolacta Bioscience
Feb 19, 2026, 00:00 ET A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely preterm infants in Japan: past,
More news about: Prolacta Bioscience
Feb 18, 2026, 14:00 ET Reddy Ice Announces Successful Closing of the Acquisition of Arctic Glacier
Reddy Ice is a portfolio company of SCI Capital Partners LP ("SCI") and a leading manufacturer and distributor of packaged ice in the United States and Mexico."We are pleased to welcome Arctic Glacier into the Reddy Ice and SCI family and excited about the value we can unlock as
More news about: Reddy Ice, LLC
Feb 18, 2026, 09:03 ET A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely preterm infants in Japan: past,
More news about: Prolacta Bioscience
Feb 17, 2026, 12:54 ET Lenire zeigt durchgängig positive Ergebnisse für Tinnitus-Patienten in den USA in der zweiten Peer-Review-Real-World-Studie
Standorten. Mitteilungen aus der Natur (2024)Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep.US VA Benefits Report Fiscal Year 2024:
More news about: Neuromod Devices
Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
Faustman DL, Davis M, Kuhtreiber WM. TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases. Int J Mol Sci. 2025 Aug 14;26(16):7839. doi: 10.3390/ijms26167839. PMID: 40869160; PMCID: PMC12386426.
More news about: Nektar Therapeutics
Feb 17, 2026, 05:30 ET Lenire Shows Consistent Positive Results for U.S. Tinnitus Patients in 2nd Peer-Reviewed Real-World Study
controlled pivotal trial. Nature communications (2024)Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep.US VA Benefits Report Fiscal Year 2024:
More news about: Neuromod Devices
Feb 17, 2026, 05:30 ET Lenire Shows Consistent Positive Results for U.S. Tinnitus Patients in 2nd Peer-Reviewed Real-World Study
controlled pivotal trial. Nature communications (2024)Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep.US VA Benefits Report Fiscal Year 2024:
More news about: Neuromod Devices